X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (19) 19
humans (16) 16
oncology (15) 15
arrangements or adaptations of heating, cooling, ventilating,or other air-treating devices specially for passenger or goodsspaces of vehicles (10) 10
performing operations (10) 10
transporting (10) 10
vehicles in general (10) 10
female (9) 9
immunotherapy (9) 9
lymphocytes (8) 8
vaccination (8) 8
animals (7) 7
cancer (7) 7
cytotoxicity (7) 7
male (7) 7
middle aged (7) 7
hepatocellular carcinoma (6) 6
mice (6) 6
mutation (6) 6
patients (6) 6
adult (5) 5
aged (5) 5
chemotherapy (5) 5
dendritic cells (5) 5
hla-dr (5) 5
immunology (5) 5
melanoma (5) 5
peptides (5) 5
responses (5) 5
survival (5) 5
tumors (5) 5
antigen (4) 4
cancer immunotherapy (4) 4
cd4 (4) 4
cd4 antigen (4) 4
head and neck neoplasms - immunology (4) 4
lymphocytes t (4) 4
proteins (4) 4
therapy (4) 4
amyotrophic lateral sclerosis (3) 3
analysis (3) 3
antigens (3) 3
antigens, neoplasm - immunology (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
cd4-positive t-lymphocytes - immunology (3) 3
cell death (3) 3
clinical-trial (3) 3
drug therapy (3) 3
gene expression (3) 3
gene-expression (3) 3
head and neck cancer (3) 3
head and neck neoplasms - pathology (3) 3
head and neck neoplasms - therapy (3) 3
helper t-cell epitope (3) 3
hepatoma (3) 3
histocompatibility antigen hla (3) 3
immunity (3) 3
liver cancer (3) 3
medical prognosis (3) 3
multidisciplinary sciences (3) 3
open-label (3) 3
original research (3) 3
patient outcomes (3) 3
peptide fragments - metabolism (3) 3
peptides - immunology (3) 3
protein binding (3) 3
sorafenib (3) 3
studies (3) 3
t cell (3) 3
testis antigens (3) 3
treatment outcome (3) 3
trial (3) 3
tumor (3) 3
+ (2) 2
abiraterone (2) 2
advanced esophageal cancer (2) 2
aged, 80 and over (2) 2
algorithms (2) 2
amino acid sequence (2) 2
amino acid substitution (2) 2
amyotrophic lateral sclerosis - metabolism (2) 2
anti-pd-l1 (2) 2
anticancer properties (2) 2
antigenic determinants (2) 2
antigens, neoplasm - genetics (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
antitumor (2) 2
bacteria (2) 2
binding (2) 2
biomarker (2) 2
bladder cancer (2) 2
blockade (2) 2
cancer patients (2) 2
cancer testis antigen (2) 2
cancer therapies (2) 2
cancer vaccines (2) 2
cancer-cells (2) 2
cd4 t cell (2) 2
cd4+ t cell (2) 2
cd4-positive t-lymphocytes - pathology (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Science, ISSN 1347-9032, 05/2015, Volume 106, Issue 5, pp. 505 - 511
Recent genome‐wide cDNA microarray analysis of gene expression profiles in comprehensive tumor types coupled with isolation of cancer tissues by... 
cDNA microarray analysis | helper T‐cell epitope | tumor‐associated antigen | Cancer immunotherapy | CTL epitope | Helper T-cell epitope | Tumor-associated antigen | TESTIS ANTIGENS | VACCINATION | tumor-associated antigen | CYTOTOXIC T-LYMPHOCYTES | RESPONSES | II CLINICAL-TRIAL | CELL IMMUNITY | HLA-DR | ONCOLOGY | GENE-EXPRESSION | CD4(+) | ESOPHAGEAL CANCER | helper T-cell epitope | T-Lymphocytes, Cytotoxic - immunology | Antigens, Neoplasm - genetics | Immunotherapy - methods | Oligonucleotide Array Sequence Analysis | Antigens, Neoplasm - immunology | Humans | Peptides - immunology | Head and Neck Neoplasms - therapy | Peptides - genetics | Carcinoma, Squamous Cell - therapy | Mice, Transgenic | Th1 Cells - immunology | Carcinoma, Squamous Cell - immunology | CD4-Positive T-Lymphocytes - immunology | Epitopes - immunology | Head and Neck Neoplasms - immunology | Neoplasms - therapy | Squamous Cell Carcinoma of Head and Neck | Animals | Neoplasms - genetics | Neoplasms - immunology | Genome-Wide Association Study - methods | Clinical Trials, Phase I as Topic | Clinical Trials, Phase II as Topic | Peptides | Lung cancer | Clinical trials | Cytotoxicity | Genomes | Lymphocytes T | Vaccines | Lipopolysaccharides | Lymphocytes | Transgenic animals | Immunotherapy | Tumor necrosis factor-TNF | Antigens | Squamous cell carcinoma | Fetuses | Transgenic mice | Melanoma | Gene expression | Esophagus | CD4 antigen | Studies | Placenta | DNA microarrays | Immunogenicity | Antigen (tumor-associated) | Head and neck cancer | Histocompatibility antigen HLA | Cancer | Tumors | Review
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 05/2017, Volume 77, Issue 9, pp. 2279 - 2291
Journal Article
GENES TO CELLS, ISSN 1356-9597, 06/2017, Volume 22, Issue 6, pp. 521 - 534
The mechanism and cause of motor neuronal cell death in amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disorder, are unknown; gain of... 
CELLS | RNA-BINDING | DEPENDENT CLEAVAGE | CHAPERONES | TDP-43 | GENETICS & HEREDITY | HEAT-SHOCK | TOXICITY | AMYOTROPHIC-LATERAL-SCLEROSIS | NUCLEOCYTOPLASMIC TRANSPORT | CORRELATION SPECTROSCOPY | CELL BIOLOGY
Journal Article
Methods in Molecular Biology, ISSN 1064-3745, 2018, Volume 1709, pp. 423 - 441
Inhibitors of the molecular chaperone heat shock protein 90 (Hsp90) have been in clinical development as anticancer agents since 1998. There have been 18 Hsp90... 
Hsp90 inhibitors | HDC (Hsp90 inhibitor-drug conjugate) | HSF1 | Biomarkers | Clinical trial | Immunity | Pharmacodynamic assessment
Journal Article
Current Opinion in Oncology, ISSN 1040-8746, 03/2017, Volume 29, Issue 3, pp. 184 - 195
PURPOSE OF REVIEWT-cell checkpoint blockade has become a dynamic immunotherapy for bladder cancer. In 2016, atezolizumab, an immune checkpoint inhibitor,... 
neoantigen | urothelial carcinoma | bladder cancer | mutational burden | immune checkpoint | combination immunotherapy | biomarker | CTLA-4 BLOCKADE | MULTICENTER | BCG | METASTATIC UROTHELIAL CARCINOMA | CISPLATIN PLUS IPILIMUMAB | OPEN-LABEL | ANTI-PD-L1 ANTIBODY | ONCOLOGY | CLINICAL ACTIVITY | EXPRESSION | AVELUMAB MSB0010718C | GENITOURINARY SYSTEM | Edited by Arif Hussain
Journal Article
Journal Article
Journal Article
Journal Article
International Journal of Cancer, ISSN 0020-7136, 01/2014, Volume 134, Issue 2, pp. 352 - 366
We recently identified a novel cancer‐testis antigen, cell division cycle associated 1 (CDCA1) using genome‐wide cDNA microarray analysis, and CDCA1‐derived... 
helper T‐cell epitope | CDCA1 | cross‐priming | head and neck cancer | cancer testis antigen | cross-priming | helper T-cell epitope | LUNG | FREQUENCIES | VACCINATION | MELANOMA PATIENTS | ANTITUMOR | HLA-DR | ONCOLOGY | IMMUNOTHERAPY | CLASS-I | ANTIGEN | LYMPHOCYTES | Th1 Cells - pathology | CD8-Positive T-Lymphocytes - pathology | Humans | CD4-Positive T-Lymphocytes - pathology | Th1 Cells - immunology | Case-Control Studies | Head and Neck Neoplasms - metabolism | CD4-Positive T-Lymphocytes - immunology | Neoplasm Recurrence, Local - immunology | Neoplasm Recurrence, Local - pathology | Th1 Cells - metabolism | Cell Cycle Proteins - immunology | Neoplasm Metastasis | Flow Cytometry | Peptide Fragments - immunology | CD8-Positive T-Lymphocytes - metabolism | Platelet Membrane Glycoprotein IIb - immunology | Fibroblasts - metabolism | Recombinant Proteins - metabolism | Peptide Fragments - metabolism | Neoplasm Recurrence, Local - metabolism | CD4-Positive T-Lymphocytes - metabolism | Cell Cycle Proteins - metabolism | Cells, Cultured | HLA Antigens - immunology | Fibroblasts - pathology | HLA Antigens - metabolism | Head and Neck Neoplasms - pathology | Head and Neck Neoplasms - immunology | Animals | Recombinant Proteins - immunology | Fibroblasts - immunology | Mice | CD8-Positive T-Lymphocytes - immunology | Platelet Membrane Glycoprotein IIb - metabolism | Clinical Trials, Phase I as Topic | Clinical Trials, Phase II as Topic | Peptides | T cells | Antigenic determinants | Cell division | Cytotoxicity | T cell receptors | Head & neck cancer
Journal Article
Endocrine Journal, ISSN 0918-8959, 2012, Volume 59, Issue 1, pp. 13 - 19
Journal Article
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 12/2019
LMB-100 is a recombinant immunotoxin (iTox) consisting of a mesothelin-binding Fab for targeting and a modified exotoxin A payload. Preclinical studies showed... 
Journal Article